title: Use of recombinant factor IX and thromboelastography in a patient with hemophilia B undergoing liver transplantation: a case report.
abstract: Hemophilia B is a congenital recessive disorder caused by deficiency of coagulation factor IX (FIX). Surgical procedures can be performed in patients with hemophilia using high-purity and/or recombinant FIX, which has been shown to be safe and effective in surgical hemostasis. Liver transplantation is the only potentially curative treatment available for these patients, providing a long-term phenotypic cure for hemophilia. End-stage liver disease together with hemophilia exposes patients to greater risks of bleeding complications during the perioperative period with consequent difficulties in managing coagulopathy. The limited experiences reported by different investigators and the various strategies for clotting factor replacement make it difficult to define a single approach with respect to the optimal dose and method of administering FIX to achieve perioperative hemostasis. The limits of plasma-based coagulation tests--prothrombin time, activated partial thromboplastin time--have made thromboelastography a valid alternative in this kind of surgery. It has been demonstrated to be a useful tool for real-time analysis of clot formation using a whole-blood assay format. Further, it accurately illustrates the clinical effects of procoagulant or anticoagulant interventions. In this article, we have described the usefulness of thromboelastography to monitor the ability of high-purity FIX supplementation to restore a normal coagulation state and to guide the perioperative administration of blood products in a successful orthotopic liver transplantation in a hemophilic patient with deficiencies of factors IX and X, presenting with hepatitis C virus-related cirrhosis and hepatocellular carcinoma.
authors.affiliation: Division of Anesthesiology, University of Modena and Reggio Emilia, Modena, Italy. lesley.depietri@tin.it
authors.forename: L
authors.initials: L
authors.lastname: De Pietri
authors.forename: M
authors.initials: M
authors.lastname: Masetti
authors.forename: R
authors.initials: R
authors.lastname: Montalti
authors.forename: B
authors.initials: B
authors.lastname: Begliomini
authors.forename: A
authors.initials: A
authors.lastname: Reggiani
authors.forename: E
authors.initials: E
authors.lastname: Barbieri
authors.forename: E
authors.initials: E
authors.lastname: Biagioni
authors.forename: M
authors.initials: M
authors.lastname: Marietta
authors.forename: A
authors.initials: A
authors.lastname: Romano
authors.forename: A
authors.initials: A
authors.lastname: Pasetto
authors.forename: G E
authors.initials: GE
authors.lastname: Gerunda
mesh_terms: D005164:Factor IX / Q000627:therapeutic use*; D002836:Hemophilia B / Q000150:complications / Q000601:surgery*; D006526:Hepatitis C / Q000150:complications / Q000601:surgery; D006801:Humans; D017093:Liver Failure / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D013916:Thrombelastography
chemical_list: D011994:Recombinant Proteins; D005164:Factor IX